Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Biology of Reproduction

• Publication date

  1995-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1095/BIOLREPROD52.2.365PMID 7711205
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclophosphamide and cis-dichlorodiammine platinum (11)

  2004cited by this paper
• Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease

  2004cited by this paper
• Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist.

  1993cited by this paper
• Influence of a gonadotrophin-releasing hormone agonist and gonadotrophins on morphometric characteristics of the population of small ovarian follicles in cynomolgus monkeys (Macaca fascicularis).

  1992cited by this paper
• Gonadal protection and fecundity rates in cyclophosphamide-treated rats.

  1991cited by this paper
• Effect of cyclophosphamide on mouse oocyte in vitro fertilization and cleavage: recovery.

  1991cited by this paper
• Cancer statistics, 1991

  1991cited by this paper
• Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.

  1990cited by this paper
• The effect of "activated" cyclophosphamide on human and rat ovarian granulosa cells in vitro.

  1990cited by this paper
• Gonadotropin-releasing hormone analogs inhibit primate granulosa cell steroidogenesis via a mechanism distinct from that in the rat.

  1990cited by this paper
• Gonadotropin-releasing hormone agonist inhibits physiologic ovarian follicular loss in rats.

  1989cited by this paper
• Effect of cyclophosphamide on the immature rat ovary.

  1989cited by this paper
• Chemotherapy-induced premature ovarian failure: mechanisms and prevention.

  1989cited by this paper
• Immunoreactive inhibin secretion by the hypophysectomized female rat: demonstration of the modulating effect of gonadotropin-releasing hormone and estrogen through a direct ovarian site of action.

  1989cited by this paper
• The Ontogeny of Immunoreactive, Endogenous FSH and LH in the Rat Ovary during Early Folliculogenesis 1

  1989cited by this paper
• Inhibition of rat ovarian [3H]thymidine uptake by luteinizing hormone-releasing hormone agonists: a possible mechanism for preventing damage by cytotoxic agents.

  1988cited by this paper
• The effect of "activated" cyclophosphamide on rat granulosa cells in vitro.

  1988cited by this paper
• A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats.

  1985cited by this paper
• Continuous [3H] thymidine infusion: a method for the study of follicular dynamics.

  1984cited by this paper
• Cell cycle effects of alkylating agents.

  1984cited by this paper
• The effect of combination chemotherapy on ovarian function in women treated for hodgkin's disease

  1983cited by this paper
• Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease.

  1981cited by this paper
• Development of the gonad in normal and anencephalic human fetuses.

  1980cited by this paper
• Pregnancy outcome following cancer chemotherapy.

  1980cited by this paper
• Effects of long-term estrogen replacement therapy. I. Metabolic effects.

  1979cited by this paper
• Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function.

  1979cited by this paper
• The growth of follicles in the rat ovary under the influence of Busulphan and Endoxan®

  1978cited by this paper
• Hormonal regulation of ovarian cellular proliferation.

  1978cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper
• Effects of fetal or maternal hypophysectomy on endocrine organs and body weight in infant rhesus monkeys (Macaca mulatta): with particular emphasis on oogenesis.

  1977cited by this paper
• Cyclophosphamide-induced ovarian failure.

  1973cited by this paper
• Cyclophosphamide and reproductive function.

  1972cited by this paper
• Changes in Mouse Ovaries After Prolonged Treatment with Cyclophosphamide 1

  1970cited by this paper

• Decoding premature ovarian insufficiency: A full spectrum review from epidemiology to management with emphasis on cyclophosphamide-evoked ovarian injury.

  2025cites this paper
• Preservation of ovarian endocrine function in patients with lymphoma: a systematic review

  2025cites this paper
• Establishing the baseline: understanding follicle activation morphometrics in multiple mammalian species.

  2025cites this paper
• Clinical Strategies for Counteracting Human Ovarian Aging: Molecular Background, Update, and Outlook

  2025cites this paper
• Withanolide derivatives: natural compounds with anticancer potential offer low toxicity to fertility and ovarian follicles in mice

  2024cites this paper
• Gonadotropin-releasing hormone agonists as a chance for motherhood in the future

  2024cites this paper
• Zishen Yutai pills restore fertility in premature ovarian failure through regulating arachidonic acid metabolism and the ATK pathway.

  2024cites this paper
• Fertility-sparing treatment in cancer patients: how can we help in the 21st century?

  2024cites this paper
• Navigating Fertility Preservation Options in Gynecological Cancers: A Comprehensive Review

  2024cites this paper
• Overactivation or Apoptosis: Which Mechanisms Affect Chemotherapy-Induced Ovarian Reserve Depletion?

  2023cites this paper
• Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve.

  2023cites this paper
• Research Progress of Protective Effect of Drug Therapy on Fertility in Female Patients with Lymphoma

  2023influential citation
• GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation

  2022cites this paper
• Chemotherapy-Related Structural Changes in Cancer: Effect of GnRH Antagonist in the Ovarian Follicles

  2022cites this paper
• Hormonal Suppression for Ovarian Protection

  2022cites this paper
• Gonadotropin-releasing hormone agonists for ovarian protection during breast cancer chemotherapy: a systematic review and meta-analysis

  2022cites this paper
• Medical Treatments for Ovarian Protection

  2022cites this paper
• Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue

  2021cites this paper
• Adipose-Derived Mesenchymal Stem Cells: A Promising Tool in the Treatment of pre mature ovarian failure.

  2021cites this paper
• Preventive effect of swim bladder hydrolysates on cyclophosphamide‐induced ovarian injury in mice

  2021cites this paper
• Evaluation of the Ovarian Reserve in Women With Systemic Lupus Erythematosus

  2021cites this paper
• Peptide Hormone Regulation of DNA Damage Responses.

  2020cites this paper
• Diminished Ovarian Reserve Chemotherapy-Induced Mouse Model: A Tool for the Preclinical Assessment of New Therapies for Ovarian Damage

  2020cites this paper
• Normas

  2020cites this paper
• Implications of non-physiological ovarian primordial follicle activation for fertility preservation.

  2020cites this paper
• Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).

  2020cites this paper
• Prevention of Gonadotoxicity

  2020cites this paper
• Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction.

  2020cites this paper
• Use of Gonadotropin-Releasing Hormone Analogs in Children: Update by an International Consortium

  2019cites this paper
• Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application.

  2019cites this paper
• Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer

  2019cites this paper
• Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells

  2019cites this paper
• Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer

  2019cites this paper
• Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy

  2019cites this paper
• Clinical Studies Investigating the Use of Leuprorelin in Breast Cancer Patients from Asia

  2019cites this paper
• Diminished Ovarian Reserve Chemotherapy-Induced Mouse Model: A Tool for the Preclinical Assessment of New Therapies for Ovarian Damage.

  2019cites this paper
• CMAR_A_204069 4273..4282

  2019cites this paper
• Fertility Risk with Cancer Therapy

  2019cites this paper
• Consequences of chemotherapeutic agents on primordial follicles and future clinical applications

  2019cites this paper
• The Impact of Chemotherapy on the Ovaries: Molecular Aspects and the Prevention of Ovarian Damage

  2019cites this paper
• Conservative management of reproductive cancers. Ovarian protection during treatment.

  2019cites this paper
• Selenium Supplementation and Gonadotropin Releasing Hormone Agonist Alleviate the Gonadotoxicity of Cyclophosphamide in Adult Mice

  2019cites this paper
• Female Fertility Preservation through Stem Cell-based Ovarian Tissue Reconstitution In Vitro and Ovarian Regeneration In Vivo

  2019cites this paper
• Phase II study of Goserelin for ovarian protection in premenopausal patients receiving cyclophosphamide containing chemotherapy : menstruation outcome

  2018cites this paper
• Preventing ovarian failure associated with chemotherapy

  2018cites this paper
• Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice

  2018cites this paper
• Contrast-enhanced ultrasound for ovary assessment in a murine model: preliminary findings on the protective role of a gonadotropin-releasing hormone analogue from chemotherapy-induced ovarian damage

  2018cites this paper
• Gonadotropin‐releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta‐analysis

  2018cites this paper
• Fertility Preservation by Endocrine Suppression of Ovarian Function Using Gonadotropin-Releasing Hormone Agonists: The End of the Controversy?

  2018cites this paper
• Onco-fertilité : Impact des facteurs influençant la réserve ovarienne après chimiothérapie

  2018cites this paper
• Fertility preservation for adolescent and young adult cancer patients in Japan

  2018cites this paper
• Fertility Preservation in the Pediatric Setting

  2017cites this paper
• Chapter 108 FERTILITY ISSUES IN THE HEMATOLOGIC MALIGNANCIES

  2017cites this paper
• Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients.

  2017cites this paper
• Fertility Issues in Patients with Breast Cancer or Survivors

  2017cites this paper
• Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy

  2017cites this paper
• GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial

  2017cites this paper
• Preservation of Reproductive Function in the Female

  2017cites this paper
• Critical Care For Young Women - Before Chemotherapy: Preserving Fertility Using GnRH Agonists

  2016cites this paper
• Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial

  2016cites this paper
• Endocrine prevention of chemotherapy-induced ovarian failure.

  2016cites this paper
• [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].

  2016cites this paper
• Prevention of chemotherapy-induced ovarian damage.

  2016cites this paper
• Endocrine prevention of chemotherapy-induced ovarian failure

  2016cites this paper
• LH prevents cisplatin-induced apoptosis in oocytes and preserves female fertility in mouse

  2016influential citation
• Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.

  2016cites this paper
• Preventive Effects of a Novel Polysaccharide from Sepia esculenta Ink on Ovarian Failure and Its Action Mechanisms in Cyclophosphamide-Treated Mice.

  2016cites this paper
• Running Title: Protection from acute DXR toxicity in marmoset ovary.

  2015cites this paper
• Pharmacological options for the protection of ovarian function in patients undergoing chemotherapy

  2015cites this paper
• Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.

  2015cites this paper
• Cetrorelix preserves follicular viability in Cyclophosphamid-induced ovarian toxicity

  2015cites this paper
• Preserving fertility when choosing chemotherapy regimens – the role of gonadotropin-releasing hormone agonists

  2015cites this paper
• GNRH agonists and antagonists in rescue for cyclophosphamide-induced ovarian damage: friend or foe?

  2015cites this paper
• Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in PremenopausalWomen Undergoing Chemotherapy for Early-Stage Breast Cancer

  2015cites this paper
• The past, present and future of fertility preservation in cancer patients.

  2015cites this paper
• Irbesartan, an angiotensin II receptor antagonist, with selective PPAR‐gamma‐modulating activity improves function and structure of chemotherapy‐damaged ovaries in rats

  2015cites this paper
• Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice

  2015cites this paper
• Use of GnRH Agonists in Fertility Preservation in Female Patients with Hematological Malignancy

  2015cites this paper
• Dexrazoxane Abrogates Acute Doxorubicin Toxicity in Marmoset Ovary1

  2015cites this paper
• Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?

  2015cites this paper
• Oncofertility in Gynecologic Malignant Tumors

  2015cites this paper
• Orthotopic Transplantation of Cryopreserved Mouse Ovaries and Gonadotrophin Releasing Hormone Analogues in the Restoration of Function following Chemotherapy-Induced Ovarian Damage

  2015cites this paper
• Current Clinical Approaches to Protecting the Ovary: GnRH Analogues

  2015cites this paper
• Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model

  2015cites this paper
• Reproductive options for female cancer patients: balancing hope and realistic expectation

  2014cites this paper
• The feasibility and efficacy of gonadotropin-releasing hormone agonists for prevention of chemotherapy induced ovarian failure in patient with gynecological malignancies

  2014cites this paper
• Fertility preservation in female cancer patients: an emerging challenge for physicians.

  2014cites this paper
• Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis.

  2014cites this paper
• Hormonelle Therapien zur Fertilitätsprotektion

  2014cites this paper
• Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials.

  2014cites this paper
• Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents.

  2014cites this paper
• Protection from cyclophosphamide-induced ovarian damage with bone marrow-derived mesenchymal stem cells during puberty

  2014cites this paper
• Ovarian aging and premature ovarian failure.

  2014cites this paper
• 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.

  2014cites this paper
• Neoadjuvant intra-arterial chemotherapy followed by total laparoscopic radical trachelectomy in stage IB1 cervical cancer.

  2014cites this paper
• Reprodukční ochrana u dospívajících dívek s maligním onemocněním

  2014cites this paper
• Chemotherapy for gynaecological malignancies and fertility preservation

  2014cites this paper
• Fertility in Hodgkin lymphoma survivors

  2014cites this paper
• Qualification biologique des greffons de tissu ovarien autoconservé : Contribution à la recherche de maladie résiduelle en cas de pathologie néoplasique

  2014cites this paper
• Protection of ovarian function during chemotherapy for ovarian cancer.

  2014cites this paper